首页> 外文期刊>国际肝胆胰疾病杂志(英文版) >Plasma exchange-centered artiifcial liver support system in hepatitis B virus-related acute-on-chronic liver failure:a nationwide prospective multicenter study in China
【24h】

Plasma exchange-centered artiifcial liver support system in hepatitis B virus-related acute-on-chronic liver failure:a nationwide prospective multicenter study in China

机译:以血浆交换为中心的人工肝支持系统治疗乙型肝炎病毒相关的慢性慢性肝功能衰竭:中国一项全国性的前瞻性多中心研究

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: Plasma exchange (PE)-centered artiifcial liver support system reduced the high mortality rate of hepa-titis B virus (HBV)-related acute-on-chronic liver failure (ACLF). But the data were diverse in different medical centers. The present prospective nationwide study was to evaluate the effects of PE on patients with HBV-ACLF at different stages. METHODS: From December 2009 to December 2011, we eval-uated 250 patients at different stages of HBV-ACLF from 10 major medical centers in China. All the laboratory parameters were collected at admission, before and after PE. RESULTS: Among the 250 patients who underwent 661 rounds of PE, one-month survival rate was 61.6%; 141 (56.4%) showed improvement after PE. Variables such as age (P=0.000), levels of total bilirubin (TB,P=0.000), direct bilirubin (P=0.000), total triglycerides (P=0.000), low-density lipoprotein (P=0.022), Na+ (P=0.014), Cl– (P=0.038), creatinine (Cr,P=0.007), ifbrinogen (P=0.000), prothrombin time (PT,P=0.000), white blood cell (P=0.000), platelet (P=0.003) and MELD (P=0.000) were signiifcantly related to prognosis. Multivariate logistic regression analysis showed that age, disease stage, TB, Cr and PT levels were independent risk factors of mortality among HBV-ACLF patients. CONCLUSIONS: PE can improve the clinical outcome of pa-tients with HBV-ACLF. Levels of TB, Cr and PT, age and disease stage help to predict prognosis.
机译:背景:以血浆交换(PE)为中心的人工肝支持系统降低了乙型肝炎病毒(HBV)相关的慢性慢性肝衰竭(ACLF)的高死亡率。但是,不同医疗中心的数据各不相同。目前的这项全国性前瞻性研究旨在评估PE在不同阶段对HBV-ACLF患者的影响。 方法:从2009年12月至2011年12月,我们评估了来自中国10个主要医疗中心的250例不同阶段HBV-ACLF的患者。 PE入院前,入院后均收集所有实验室参数。 结果:250例接受661轮PE的患者中,一个月生存率为61.6%; PE后有141例(56.4%)改善。诸如年龄(P = 0.000),总胆红素(TB,P = 0.000),直接胆红素(P = 0.000),总甘油三酸酯(P = 0.000),低密度脂蛋白(P = 0.022),Na +( P = 0.014),Cl–(P = 0.038),肌酐(Cr,P = 0.007),纤维蛋白原(P = 0.000),凝血酶原时间(PT,P = 0.000),白细胞(P = 0.000),血小板( P = 0.003)和MELD(P = 0.000)与预后显着相关。多元logistic回归分析显示,年龄,疾病分期,TB,Cr和PT水平是HBV-ACLF患者死亡的独立危险因素。 结论:PE可以改善HBV-ACLF患者的临床结局。 TB,Cr和PT的水平,年龄和疾病阶段有助于预测预后。

著录项

  • 来源
    《国际肝胆胰疾病杂志(英文版)》 |2016年第3期|275-281|共7页
  • 作者单位

    State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, and Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, First Afifliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China;

    Department of Infectious Diseases, First Afifliated Hospital of Suzhou University, Suzhou 215006, China;

    Department of Infectious Diseases, Third Afifliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China;

    Insti-tute of Infectious Diseases, Southwest Hospital, Third Military Medical University, Chongqing 400038, China;

    Department of Infec-tious Diseases, First Afifliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China;

    Department of Infectious Diseases, Ruijin Hos-pital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China;

    Department of Infectious Diseases, Infectious Diseases Hospital Afifliated to Fujian Medical University, Fuzhou 350025, China;

    State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, and Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, First Afifliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China;

    State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, and Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, First Afifliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China;

    State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, and Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, First Afifliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China;

    State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, and Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, First Afifliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China;

    State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, and Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, First Afifliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China;

    State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, and Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, First Afifliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China;

    Liver Failure Therapy and Research Center,302 Hospital of People’s Liberation Army, Beijing 100039, China;

    Department of Hepatology, Third Central Clinical College of Tianjin Medical University, Tianjin 300170, China;

    Artiifcial Liver Center, You’an Hospital, Capital Medical Univer-sity, Beijing 100069, China;

  • 收录信息 中国科学引文数据库(CSCD);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-19 03:39:14
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号